EMA Lapsed: Zevalin (ibritumomab tiuxetan) — Ceft Biopharma s.r.o.

View source ↗

Summary

The EMA indicates Zevalin (ibritumomab tiuxetan) marketing authorization in the EU has lapsed. The MAH is Ceft Biopharma s.r.o., and the therapeutic area is fol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Zevalin (ibritumomab tiuxetan)

Snippet

Status: Lapsed. Therapeutic area: Lymphoma, Follicular. MAH: Ceft Biopharma s.r.o.. Decision date: 10/06/2021